AMENDMENTS TO THE CLAIMS

1. (Previously Presented) A method of treating or remedying psoriasis in a subject in need thereof, comprising administering to the subject a therapeutically effective dose of at least one calcitonin gene-related peptide (CGRP) antagonist compound in a pharmaceutically acceptable formulation.

2. (Previously Presented) The method according to claim 1, wherein the at least one CGRP antagonist compound is selected from the group consisting of: 4-sulfinyl benzamide compounds, 3,4-dinitrobenzamide compounds, benzamidazolinyl piperadine compounds, anti-CGRP antibodies, a peptide comprising SEQ ID NO:1, tryptase active polypeptide, BIBN4096BS, and heparin.

3. (Previously Presented) The method according to claim 1, wherein the at least one CGRP antagonist compound is administered locally.

4. (Cancelled)

5. (Original) The method according to claim 1, wherein the CGRP antagonist compound is administered topically.

6-14. (Cancelled)

15. (Previously Presented) The method according to claim 1, wherein the at least one CGRP antagonist is administered topically, dermally, intradermally, subcutaneously, via dermal infusion, or via subcutaneous infusion.

16-17. (Cancelled)

18. (Previously Presented) The method according to claim 1, wherein said at least one CGRP antagonist compound comprises a polypeptide of SEQ ID NO:1.

19. (Previously Presented) The method according to claim 1, wherein said at least one CGRP antagonist compound consists essentially of a polypeptide of SEQ ID NO:1.

20. (Previously Presented) The method according to claim 1, wherein the at least one CGRP antagonist compound is a CGRP peptide which lacks wild type CGRP activity and binds to CGRP receptor.

21-22. (Cancelled)

23. (**New**) The method according to claim 1, wherein the at least one CGRP antagonist is administered dermally, intradermally, subcutaneously, via dermal infusion, via subcutaneous infusion, or via microdialysis.

24. (**New**) The method according to claim 1, wherein the at least one CGRP antagonist compound is BIBN4096BS.

25. (**New**) The method according to claim 1, wherein the pharmaceutically acceptable formulation consists essentially of a CGRP antagonist and an excipient.

26. (**New**) The method according to claim 1, further comprising exposing the subject to UVB radiation and/or administering a cell division inhibitor to the subject.